Prediction of response to spironolactone treatment in patients with resistant arterial hypertension: insights from the ASPIRANT trial

被引：0

作者：

Vaclavik, J. ^{[1
]}

Kocianova, E. ^{[1
]}

Sedlak, R. ^{[2
]}

Plachy, M. ^{[3
]}

Navratil, K. ^{[4
]}

Plasek, J. ^{[5
]}

Jarkovsky, J. ^{[6
]}

Vaclavik, T. ^{[7
]}

Svestak, M. ^{[8
]}

Taborsky, M. ^{[1
]}

机构：

[1] Palacky Univ, Fac Med & Dent, Dept Internal Med Cardiol 1, CR-77147 Olomouc, Czech Republic

[2] Prostejov Hosp, Dept Internal Med, Prostejov, Czech Republic

[3] Masaryk Univ, St Annes Fac Hosp, Dept Internal Med 2, Brno, Czech Republic

[4] Mil Hosp, Dept Internal Med, Olomouc, Czech Republic

[5] Univ Hosp Ostrava, Dept Internal Med, Ostrava, Czech Republic

[6] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic

[7] Univ Econ, Fac Informat & Stat, Stat & Probabil Dept, Prague, Czech Republic

[8] Prostejov Hosp, Dept Lab Med, Prostejov, Czech Republic

来源：

EUROPEAN HEART JOURNAL | 2011年 / 32卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：645 / 645

页数：1

共 50 条

[1] Prediction of response to spironolactone treatment in patients with resistant arterial hypertension: insights from the ASPIRANT trial
Vaclavik, J.
Kocianova, E.
Sedlak, R.
Plachy, M.
Navratil, K.
Plasek, J.
Jarkovsky, J.
Vaclavik, T.
Svestak, M.
Taborsky, M.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 : 645 - 645
[2] Effect of spironolactone treatment on microalbuminuria and proteinuria in patients with resistant arterial hypertension: insights from the ASPIRANT trial
Kocianova, E.
Vaclavik, J.
Sedlak, R.
Plachy, M.
Navratil, K.
Plasek, J.
Jarkovsky, J.
Vaclavik, T.
Husar, R.
Taborsky, M.
EUROPEAN HEART JOURNAL, 2011, 32 : 887 - 887
[3] Addition of spironolactone in patients with resistant arterial hypertension:: The ASPIRANT trial
Vaclavik, J.
Plachy, M.
Lacnak, B.
JOURNAL OF HYPERTENSION, 2008, 26 : S456 - S456
[4] Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: Insights from the aspirant trial
Vaclavik, Jan
Sedlak, Richard
Jarkovsky, Jiri
Kocianova, Eva
Taborsky, Milos
BIOMEDICAL PAPERS-OLOMOUC, 2014, 158 (03): : 384 - 390
[5] ADDITION OF SPIRONOLACTONE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION (ASPIRANT) - STUDY PROTOCOL
Vaclavik, Jan
Sedlak, Richard
Plachy, Martin
Navratil, Karel
Plasek, Jiri
Husar, Roman
Kocianova, Eva
Taborsky, Milos
BIOMEDICAL PAPERS-OLOMOUC, 2011, 155 (02): : 143 - 148
[6] Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial
Vaclavik, J.
Sedlak, R.
Plachy, M.
Navratil, K.
Plasek, J.
Jarkovsky, J.
Vaclavik, T.
Husar, R.
Kocianova, E.
Taborsky, M.
EUROPEAN HEART JOURNAL, 2011, 32 : 500 - 501
[7] Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT) A Randomized, Double-Blind, Placebo-Controlled Trial
Vaclavik, Jan
Sedlak, Richard
Plachy, Martin
Navratil, Karel
Plasek, Jiri
Jarkovsky, Jiri
Vaclavik, Tomas
Husar, Roman
Kocianova, Eva
Taborsky, Milos
HYPERTENSION, 2011, 57 (06) : 1069 - U94
[8] Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT-EXT): a randomized, double-blind, placebo-controlled trial
Vaclavik, J.
Sedlak, R.
Jarkovsky, J.
Kocianova, E.
Taborsky, M.
EUROPEAN HEART JOURNAL, 2013, 34 : 108 - 108
[9] Effect of Spironolactone in Resistant Arterial Hypertension A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT)
Vaclavik, Jan
Sedlak, Richard
Jarkovsky, Jiri
Kocianova, Eva
Taborsky, Milos
MEDICINE, 2014, 93 (27)
[10] Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial (vol 57, pg 1069, 2011)
Vaclavik, J.
Sedlak, R.
Plachy, M.
Navratil, K.
Plasek, J.
Jarkovsky, J.
Vaclavik, T.
Husar, R.
Kocianova, E.
Taborsky, M.
HYPERTENSION, 2015, 65 (02)

← 1 2 3 4 5 →